Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One

[Image: see text] Proteolysis targeting chimera (PROTAC)-mediated protein degradation has prompted a radical rethink and is at a crucial stage in driving a drug discovery transition. To fully harness the potential of this technology, a growing paradigm toward enriching PROTACs with other therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Salerno, Alessandra, Seghetti, Francesca, Caciolla, Jessica, Uliassi, Elisa, Testi, Eleonora, Guardigni, Melissa, Roberti, Marinella, Milelli, Andrea, Bolognesi, Maria Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340767/
https://www.ncbi.nlm.nih.gov/pubmed/35816671
http://dx.doi.org/10.1021/acs.jmedchem.2c00302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340767/
https://www.ncbi.nlm.nih.gov/pubmed/35816671
http://dx.doi.org/10.1021/acs.jmedchem.2c00302

Ejemplares similares